Clinical Trial Update: BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants [Phase 1]

View source ↗

Summary

Phase 1 trial of the BZLF1 peptide vaccine OSU-2131 with QS-21 to prevent Epstein-Barr virus–related cancers in patients awaiting solid organ transplants; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Related Lymphoproliferative Disorder
• Epstein-barr Virus Related Malignant Neoplasms
• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• BZLF1 peptide vaccine (OSU-2131) (BZLF1 peptide vaccine)
• QS-21 (Quillaja saponin)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5 | Phase 1 | Status: SUSPENDED